These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21641365)

  • 21. [Microalbuminuria--an independent indication for administration of ACE inhibitors: role of fosinopril (PREVEND IT trial)].
    Ter Arkh; 2005; 77(9):84-8. PubMed ID: 16281498
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
    Yokoyama M; Origasa H;
    Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    DeFilippis AP; Bansal S; Blumenthal RS
    N Engl J Med; 2008 Jan; 358(2):194; author reply 194-5. PubMed ID: 18193527
    [No Abstract]   [Full Text] [Related]  

  • 24. [After several years of statin therapy. Long-term prevention of cardiac death].
    MMW Fortschr Med; 2003 Feb; 145(8):56. PubMed ID: 12661448
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
    Prescrire Int; 2011 Apr; 20(115):94. PubMed ID: 21648210
    [No Abstract]   [Full Text] [Related]  

  • 27. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    McEvoy JW; Margey R; Blake GJ
    N Engl J Med; 2008 Jan; 358(2):193; author reply 194-5. PubMed ID: 18184967
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
    van der Harst P; Asselbergs FW; Hillege HL; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2008 Jul; 102(2):223-5. PubMed ID: 18602526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 31. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.
    Stewart RA; North FM; Sharples KJ; Simes RJ; Tonkin AM; White HD;
    N Z Med J; 2008 Feb; 121(1269):11-23. PubMed ID: 18278078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
    Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
    Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HOPE study: comparison with other trials of secondary prevention.
    Otterstad JE; Sleight P
    Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Tsubokura M; Kami M
    N Engl J Med; 2008 Jan; 358(2):193-4; author reply 194-5. PubMed ID: 18193526
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs.
    Ikeda T; Sakurai J; Nakayama D; Takahashi Y; Matsuo K; Shibuya Y; Gomi T; Moriya H; Kobayashi S
    Am J Hypertens; 2004 Jun; 17(6):502-6. PubMed ID: 15177522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
    Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
    Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-lowering therapy and risk of coronary events.
    Blakely JA
    JAMA; 2003 Apr 23-30; 289(16):2070-1; author reply 2071-2. PubMed ID: 12709461
    [No Abstract]   [Full Text] [Related]  

  • 39. Lipid-lowering therapy and risk of coronary events.
    Taylor WC
    JAMA; 2003 Apr 23-30; 289(16):2070; author reply 2071-2. PubMed ID: 12709462
    [No Abstract]   [Full Text] [Related]  

  • 40. Lipid-lowering therapy and risk of coronary events.
    Mascitelli L; Pezzetta F
    JAMA; 2003 Apr 23-30; 289(16):2071; author reply 2071-2. PubMed ID: 12709464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.